Acutaas Chemicals Ltd · NSE:ACUTAAS
Acutaas Chemicals — Ami Organics — Q4 FY2025 Earnings Presentation
41 slides from Acutaas Chemicals's earnings presentation, May 2, 2025
Slide 1: Filing cover letter to stock exchanges
4q@ Ami Organics Limited ® oe eo e o CIN. : L24100GJ2007PLC051093 Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India. May 2, 2025 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India
Slide 2: Investor Presentation May 2025
Investor Presentation M AY 2 0 2 5 BSE : 543349 | NSE : AMIORG | www.amiorganics.com 1
Slide 3: Table of Contents
Table of Contents 01 02 03 Q4 & FY25 Results Company Overview Advanced Pharma Intermediate 04 05 Specialty Chemicals Working towards better tomorrow 2
Slide 4: 1. Q4 & FY25 Results
1. Q4 & FY25 Results ➢ Management Commentary ➢ Q4FY25 Earnings & Business Highlights ➢ Q4FY25 Financial Performance – Key Metrics ➢ FY25 Financial Performance – Key Metrics ➢ Q4 & FY25 Financial Performance – P&L Statement ➢ Financial Performance over the years – Key Metrics ➢ Financial Performance
Slide 5: Management Commentary
Management Commentary “I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed ₹1,000 crore in revenue—a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including
Slide 6: Q4FY25 Earnings & Business Highlights
Q4FY25 Earnings & Business Highlights ➢ Revenue from operations for Q4FY25 grew by 37.1% YoY to Rs. 3,085 mn ➢ The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ ➢ EBITDA for the quarter came at Rs. 850 mn up 96.8% YoY compared to Rs. 432 mn in Q4FY24. ➢ EBITDA margin
Slide 7: Q4FY25 Financial Performance – Key Metrics
Q4FY25 Financial Performance – Key Metrics Revenue from Operations (Rs Mn) YoY Growth 44.0% 0.8% 37.1% Q4FY24 Q4FY25 3,085 2,728 2,250 1,896 353 357 Advance Intermediates Specialty Chemicals Total EBITDA & EBITDA Margin PAT (Rs Mn) 27.5% (Rs Mn) 20.3% 19.2% 11.4% 432 850 257 627 Q4FY24 Q4FY25 Q4FY24
Slide 8: FY25 Financial Performance – Key Metrics
FY25 Financial Performance – Key Metrics Revenue from Operations (Rs Mn) YoY Growth 50.4% 2.2% 40.3% FY24 FY25 10,069 8,540 7,175 5,678 1,497 1,529 Advance Intermediates Specialty Chemicals Total EBITDA & EBITDA Margin PAT (Rs Mn) (Rs Mn) 23.0% 15.9% 17.9% 11.3% 1,285 2,321 808 1,604 FY24 FY25 FY24
Slide 9: Q4 & FY25 Financial Performance – P&L Statement
Q4 & FY25 Financial Performance – P&L Statement Particulars (Rs. Mn) Q4FY25 Q4FY24 YoY Q3FY25 QoQ FY25 FY24 YoY Revenue from Operations 3,085 2,250 37.1% 2,750 12.2% 10,069 7,175 40.3% COGS 1,625 1,350 1,478 5,522 4,117 Gross Profit 1,460 900 62.3% 1,272 14.8% 4,547 3,058 48.7% Gross Margin 47.3% 40
Slide 10: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations- Growth Trends (Rs Mn) FY20 FY21 FY22 FY23 FY24 FY25 FY20-25 CAGR: 29.8% 83.3% 33.3% 10,069 8,540 7,175 5,678 6,170 5,180 5,201 4,270 3,240 3,406 2,322 2,396 932 990 1,497 1,529 74 166 Advance Intermediates Chemicals Total Re
Slide 11: Financial Performance over the years – Key Metrics (cont’d)
Financial Performance over the years – Key Metrics (cont’d) EBITDA and EBITDA Margins (%) PAT and PAT Margins (%) 23.5% 23.0% 20.2% 15.9% 15.9% 17.1% 13.8% 11.5% 19.9% 17.9% 13.5% 11.3% 410 802 1,052 1,227 1,285 2,321 275 540 719 833 808 1,604 FY20 FY21 FY22 FY23 FY24 FY25 FY20 FY21 FY22 FY23 FY24 F
Slide 12: Financial Performance over the years - Profit and Loss
Financial Performance over the years - Profit and Loss Particulars (INR mn) FY21 FY22 FY23 FY24 FY25 Revenue from Operations 3,406 5,201 6,167 7,175 10,069 Other Income 14 28 43 75 169 Total Income 3,420 5,229 6,210 7,250 10,238 Cost of materials consumed 1,749 2,823 3,459 4,402 5,698 Changes in inv
Slide 13: Financial Performance over the years - Balance Sheet
Financial Performance over the years - Balance Sheet Assets (INR mn) FY21 FY22 FY23 FY24 FY25 Equity and Liabilities (INR FY21 FY22 FY23 FY24 FY25 mn) Property, plant and 1,422 1,584 1,844 3,229 4,629 equipment Shareholder's equity 1,669 5,223 5,939 6,828 13,201 Right of use assets 184 194 374 372 4
Slide 14: Shareholder Information
Shareholder Information Shareholding as on 31st March 2025 Share Information as on 31st March 2025 NSE Ticker AMIORG BSE Ticker 543349 Others Promoters 29.3% 36.0% Market Cap (Rs. Cr) 9,991 Shares Outstanding 8,18,68,922 3M ADTV (Shares)* 3,59,646 3M ADTV (Rs. cr)* 80.9 FII 16.5% Industry Specialty
Slide 15: 2. Company Overview
2. Company Overview ➢ Company Overview ➢ Our Journey ➢ Our Products ➢ Strong and Long-term relations with Diversified Customers across Geographies ➢ Our Manufacturing Facilities ➢ Superior R&D Capabilities ➢ Our Founders ➢ Our Leadership ➢ What makes us different 14
Slide 16: Ami Organics – At a Glance
Ami Organics – At a Glance Business Segments ➢ One of the leading Research and Development driven manufacturer of Specialty Chemicals ➢ Focused on the development and manufacturing of: • Advanced Pharmaceutical Intermediates Advanced Pharmaceutical Specialty • Specialty Chemicals Intermediates Chemi
Slide 17: The Evolution
The Evolution 2004 2005 2007 2011 Formation of partnership firm in the name of Gujarat Gas Safety Award – developing and Change in constitution from partnership firm to Implemented the Integrated “Ami Organics” implementing effective HSE Management private limited in the name of Management System Sy
Slide 18: Business Segments
Business Segments Advanced Pharmaceutical Specialty Chemicals Intermediates ➢ 550+ Products invoiced in last 5 years ➢ Parabens & Paraben formulations ➢ Methyl Salicylate ➢ Intermediates across 17+ therapeutic ➢ Niche KSMs for cosmetics, finechem and areas agrochem companies ➢ ~95% Chronic Therapy f
Slide 19: Strong and Long-term Relations with Diversified Customers across Geographies
Strong and Long-term Relations with Diversified Customers across Geographies ➢ Well established long-term relations with domestic customers as well as MNCs ~600 ~55 across large and fast-growing markets Customers Countries ➢ Diversified customer base (customer locations) 30+ ➢ Long term supply contr
Slide 20: Strong and Long-term relations with Diversified Customers (cont’d)
Strong and Long-term relations with Diversified Customers across Geographies (cont’d) Advanced Generic Pharma Intermediates (Top Clients) Innovators Specialty Chemicals (Top Clients) 19
Slide 21: State-of-the-Art Manufacturing Facilities
State-of-the-Art Manufacturing Facilities 76,891 ~1,100 Total Land Area (sq mtrs) Total Installed Capacity (KL) Sachin, Gujarat Ankleshwar, Gujarat Jhagadia, Gujarat Greater Noida, UP Picture Land Area Installed Capacity Land Area Installed Capacity Land Area Installed Capacity Land Area Installed C
Slide 22: R&D Centric Organization…
R&D Centric Organization… R&D Expenditure State-of-the-Art (INR mn) 1 R&D Lab 2 Technology 3 Equipment 65 70 77 141 168 ADL fully supported by analytical • Modern fume hood system 23,681 sq. ft. instruments like: • Autoclave State of art R&D facility at Sachin R&D expenditure as % • LCMASS • High va
Slide 23: Superior R&D Capabilities (Cont’d)
Superior R&D Capabilities (Cont’d) Our Capabilities in Key Chemistry Etherification Acylation Fluorination Nitration Esterification Bromination Diazotization Hydrogenation Alkylation Amination Chlorination & hydrolysis AMI Organics R&D Centre in Surat 22
Slide 24: Superior R&D Capabilities – Continuous Flow Reactor
Superior R&D Capabilities (Cont’d) Continuous Flow Reactor ➢ Continuous flow reactors are more efficient, and sustainable when compared to manufacturing products using traditional reactors. ➢ Successfully developed capabilities in Plug Flow, Catalytic fixed-bed flow, Tubular flow kind of reactors ➢
Slide 25: Our Founders
Our Founders ➢ Mr. Nareshkumar Patel is founder of the Company ➢ He has been associated with the Company since its inception and has extensive experience in the global generic pharma business ➢ He is responsible for handling the Chemical Engineering and Product Implementation divisions of the Compan
Slide 26: Our Leadership
Our Leadership Board of Directors Virendra Girikrishna Richa Hetal Anita Ram Mohan Mishra Maniar Goyal Gandhi Bandyopadhyay Lokhande Whole – time Non – executive, Non – executive, Non – executive Independent Whole – time Director Independent Director Independent Director Independent Director Directo
Slide 27: What Makes Us Different ?
What Makes Us Different ? Niche Product Portfolio High Entry Diversified Products to Diversified Customer Reputation for Robust Cost with a Strong Market Barriers Support Future Growth Base across Innovative Product Management / Process Share Geographies Launches Supported by Improvements Robust R&D
Slide 28: 3. Advanced Pharma Intermediate
3. Advanced Pharma Intermediate ➢ A leading Advanced Intermediate Manufacturer from India ➢ Our Business Model ➢ Uniqueness of our business model ➢ Our Strategy and Outlook ➢ Industry Overview 27
Slide 29: Advanced Pharmaceutical Intermediates
Advanced Pharmaceutical Intermediates Historical Business Performance (INR mn) 8,540 17+ 160+ FY25 Therapeutic Customers Revenue Areas CAGR 27% 8,540 in FY25 (INR mn) 5,678 5,180 4,270 3,240 25+ 15 2 FY21 FY22 FY23 FY24 FY25 Countries Process Patents Manufacturing (Customer locations) (1 patent publ
Slide 30: Our Business Model – Advanced Intermediates for Pharmaceuticals
Our Business Model – Advanced Intermediates for Pharmaceuticals Revenue breakup for FY25 CDMO ➢ Contract Manufacturing for big pharma companies 3% ➢ Exclusive long term supply contracts Regulatory market business ➢ Supplying NCE molecules to the pharma innovator companies ➢ Supplying intermediates t
Slide 31: Uniqueness of our business model
Uniqueness of our business model 1 2 3 4 5 6 Chronic Therapy Wide Product R&D Presence across Preferred Strong Customer focused Basket Leadership value chain Supplier Base ➢ ~95% of the ➢ Wider basket of ➢ First to market with ➢ AMI is present across ➢ Our unique business ➢ As one of the products ca
Slide 32: Our Strategy – Advanced Pharmaceutical Intermediates
Our Strategy – Advanced Pharmaceutical Intermediates Grow the Innovator business with more focus on CDMO opportunities S T R Commercialise products way ahead of time for drugs going off-patent in the coming years A T Continue to develop innovative products for the global market E G Y Ramp up product
Slide 33: Industry Overview (1/2)
Industry Overview (1/2) Global API Market Global Pharmaceutical Intermediates Market (USD bn) (USD bn) 6.5% CAGR 326 6.2% CAGR 51 6.1% CAGR 238 6.0% CAGR 37 177 28 2018 2023 2028E 2018 2023 2028E Global API Market Split by Therapy 15% 19% CAGR CAGR 27% 25% (2018-23) (2023-28E) 35% 33% Oncology 11% 1
Slide 34: 4. Specialty Chemicals
4. Specialty Chemicals ➢ Speciality Chemicals - Overview ➢ Our Strategy and Outlook ➢ Industry Overview 33
Slide 35: Speciality Chemicals
Speciality Chemicals Historical Business Performance (INR mn) 1,529 3 60+ FY25 Business Products Revenue Segments CAGR 74% (INR mn) ➢ Specialty Chemicals for various industries e.g. 1,497 1,529 Cosmetics, Finechem, Agrochem, etc. ➢ Battery Chemicals ➢ Semiconductor Chemicals 932 990 166 400+ 50+ 2 F
Slide 36: Our Strategy – Speciality Chemicals
Our Strategy – Speciality Chemicals Development and entry Continue to work on into newer applications improving operational having strong entry efficiencies to deliver barriers better margins Leverage the technology Grow the Battery and capability of Baba Fine Chemicals segment – Chemicals to expand
Slide 37: Industry Overview (2/2)
Industry Overview (2/2) Global Electrolyte Additives and Electrolyte Solutions Market Global Specialty Chemicals Market 20.2 (USD bn) 11.2 (USD bn) 6.5 1,219 3.4 0.8 1.6 937 2018 2023 2028E 785 Electrolyte Additives Electrolyte Solutions Global Photoresist Chemicals and Semiconductor Chemicals Marke
Slide 38: 5. Working towards better tomorrow
5. Working towards better tomorrow 37
Slide 39: ESG Focus – Working towards a Better Tomorrow
ESG Focus – Working towards a Better Tomorrow SDGs Aligned Environment GOLD 16 MW One 54% Environment EcoVadis Renewable energy Project Plant has Zero Total waste rating in Progress (11 MW project Liquid Discharge recycled already commissioned) ZERO 100% 100% Social Safety Employees covered Employee
Slide 40: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 41: Contact Us
Contact Us For more information please contact: Ami Organics Limited Ekta Srivastava Company Secretary & Compliance Officer cs@amiorganics.com Rahul Thakur Senior Manager – Investor Relations Rahul.thakur@amiorganics.com 40 © 2020 Ami Organics Limited, All Rights Reserved.